Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab plus platinum-taxane chemotherapy followed by avelumab + cetuximab maintenance in first-line recurrent/metastatic HNSCC with PD-L1 CPS 1-19
2024-512053-24-00Phase 2Authorised
- Sponsor
- GONO Foundation
- Start
- Dec 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab, avelumab, cisplatin and carboplatin in head and neck squamous cell carcinoma (HNSCC), sponsored by GONO Foundation. Primary endpoint: 6-month progression-free survival. Planned start Dec 2024; status: authorised.
02
Drugs
cetuximabavelumabcisplatincarboplatin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2024-512053-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512053-24-00.